A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma

NCT05461209 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business Decision

Conditions

Relapsed/ Refractory Multiple Myeloma

Interventions

DRUG: Talquetamab
DRUG: Belantamab Mafodotin

Sponsor

Janssen Research & Development, LLC